2/26
02:11 pm
cccc
C4 Therapeutics (CCCC) had its "overweight" rating reaffirmed by Barclays PLC.
Low
Report
C4 Therapeutics (CCCC) had its "overweight" rating reaffirmed by Barclays PLC.
2/26
02:11 pm
cccc
C4 Therapeutics (CCCC) had its "buy" rating reaffirmed by TD Cowen.
Low
Report
C4 Therapeutics (CCCC) had its "buy" rating reaffirmed by TD Cowen.
2/26
07:53 am
cccc
C4 Therapeutics beats Q4 street views [Seeking Alpha]
Low
Report
C4 Therapeutics beats Q4 street views [Seeking Alpha]
2/26
07:32 am
cccc
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
2/26
07:00 am
cccc
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Medium
Report
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
2/23
12:39 pm
cccc
C4 Therapeutics (NASDAQ:CCCC) had its price target raised by analysts at Brookline Capital Acquisition Corp. from $20.00 to $30.00. They now have a "buy" rating on the stock.
Medium
Report
C4 Therapeutics (NASDAQ:CCCC) had its price target raised by analysts at Brookline Capital Acquisition Corp. from $20.00 to $30.00. They now have a "buy" rating on the stock.
2/23
07:40 am
cccc
C4 Therapeutics to Participate in Upcoming March Conferences [Yahoo! Finance]
Medium
Report
C4 Therapeutics to Participate in Upcoming March Conferences [Yahoo! Finance]
2/23
07:10 am
cccc
C4 Therapeutics to Participate in Upcoming March Conferences
Medium
Report
C4 Therapeutics to Participate in Upcoming March Conferences
2/23
07:00 am
cccc
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
Medium
Report
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
2/9
04:01 pm
cccc
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/4
08:29 am
cccc
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
Medium
Report
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
2/4
07:00 am
cccc
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Medium
Report
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
2/2
09:05 pm
cccc
C4 Therapeutics, Inc. (CCCC): A Bull Case Theory [Yahoo! Finance]
Medium
Report
C4 Therapeutics, Inc. (CCCC): A Bull Case Theory [Yahoo! Finance]
1/26
04:01 pm
cccc
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1/21
08:40 am
cccc
Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel [Yahoo! Finance]
Low
Report
Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel [Yahoo! Finance]
1/15
03:29 pm
cccc
Clinical trial results drove insider trading: SEC [Investment Executive - News]
Low
Report
Clinical trial results drove insider trading: SEC [Investment Executive - News]
1/14
07:00 am
cccc
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
Low
Report
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
12/17
07:18 am
cccc
C4 Therapeutics (NASDAQ:CCCC) was given a new $5.00 price target on by analysts at Barclays PLC.
High
Report
C4 Therapeutics (NASDAQ:CCCC) was given a new $5.00 price target on by analysts at Barclays PLC.
12/2
08:04 am
cccc
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Medium
Report
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
12/2
07:10 am
cccc
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
Medium
Report
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.